Partial
Needs Correction
Patient Risk:
Medium
Summary
Several safety-related statements about bleeding risk and warfarin/antithrombotics are supported by the provided label excerpts, and Vascepa being an omega-3 derivative with fish oil source is consistent. However, multiple claims about supplements and interaction evidence, supplement regulatory quality, FDA regulation of Vascepa, and patent/access are not supported by the provided prescribing information excerpts and include at least one potentially overbroad or unlabelled interaction/risk assertion.
Category Scores
Accurate Statements
Vascepa is a derivative of omega-3 fatty acids used to treat high triglyceride levels.
Section 1 INDICATIONS AND USAGE states VASCEPA is indicated (1) as adjunct to maximally tolerated statin therapy to reduce risk of cardiovascular events in adult patients with elevated TG levels and (2) as adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Section 5.2 states VASCEPA contains ethyl esters of omega-3 fatty acid (EPA).
The combination of Vascepa with high doses of warfarin may increase the risk of bleeding.
Section 5.3 Bleeding: incidence of bleeding greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.
Combining Vascepa with other fish oil or omega-3 supplements may increase the risk of bleeding.
Section 7.1: some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time; monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding. Section 5.3 establishes increased bleeding with concomitant antithrombotic medications; however, the excerpt does not explicitly address other fish oil/omega-3 supplements.
There are no established interactions between Vascepa and most dietary supplements.
Not directly supported or refuted by the provided excerpts.
Combining Vascepa with other fish oil or omega-3 supplements may lower blood pressure.
Not supported by the provided excerpts (no label text provided addressing blood pressure).
Unsupported Statements
There are no established interactions between Vascepa and most dietary supplements.
The provided prescribing information excerpt does not state that there are no established interactions with dietary supplements broadly. The only interaction-related information provided is Section 7.1 concerning anticoagulants and antiplatelet agents and general omega-3 bleeding time study references.
Combining Vascepa and other fish oil or omega-3 supplements may increase the risk of bleeding.
Section 5.3 discusses bleeding risk with concomitant antithrombotic medications (e.g., warfarin) but does not specifically mention fish oil/omega-3 supplements as concomitant agents for bleeding risk in the provided excerpts.
Combining Vascepa with other fish oil or omega-3 supplements may lower blood pressure.
No provided label excerpt addresses blood pressure effects.
The FDA regulates Vascepa under prescription medication guidelines.
The provided excerpts do not include regulatory/regulatory-authority statements.
Supplements follow different regulations than prescription medications.
The provided excerpts do not discuss regulatory frameworks for supplements vs prescription products.
Supplements may have variable quality control standards.
The provided excerpts do not discuss supplement quality control.
Clinical data and research on interactions between Vascepa and supplements are limited.
No provided label excerpt states that interaction research between Vascepa and supplements is limited.
A patent covering the use of Vascepa in certain indications may expire, potentially affecting access to the medication and related therapies.
No provided label excerpt includes patent, exclusivity, or access statements.
Contradictions
Low
AI Statement
Combining omega-3 supplements with Vascepa may enhance the bleeding risk associated with omega-3s.
Label Reference
Sections 5.3 and 7.1 provided excerpts
Important Omissions
No AI claim assessed included the label's requirement to monitor for bleeding when used with concomitant anticoagulants and/or antiplatelet agents; the AI mentions bleeding risk but does not specify the labeled monitoring context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some bleeding-risk statements are partially aligned (warfarin/concomitant antithrombotics). However, several other claims about supplements (including no-established-interactions, bleeding enhancement with omega-3 supplements, and possible blood pressure lowering) are not supported by the provided label excerpts, which could mislead about interaction scope and safety monitoring needs.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Correction
Primary Issue
Multiple claims are not supported by the provided prescribing information excerpts (dietary supplement interactions evidence, regulatory statements, quality-control variability, blood pressure effect, patent/access). Interaction/bleeding claims involving fish oil/omega-3 supplements are not explicitly described in the provided label text.
Suggested Improvement
Limit claims to label-supported elements: (1) Vascepa contains omega-3 ethyl esters (EPA) and is indicated for elevated triglycerides; (2) bleeding risk is increased with concomitant antithrombotic medications such as warfarin and monitor patients receiving VASCEPA with concomitant anticoagulants/antiplatelet agents; remove or qualify supplement-regulatory/patent statements and any unsupported statements about blood pressure or broad supplement interaction absence.